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Abstract
BACKGROUND
Helicobacter pylori (H. pylori), a bacterium that infects approximately half of the
world’s population, is associated with various gastrointestinal diseases, including
peptic ulcers, non-ulcer dyspepsia, gastric adenocarcinoma, and gastric lymphoma. As the burden of antibiotic resistance increases, the need for new adjunct
therapies designed to facilitate H. pylori eradication and reduce negative distal
outcomes associated with infection has become more pressing. Characterization of
the interactions between H. pylori, the fecal microbiome, and fecal fatty acid
metabolism, as well as the mechanisms underlying these interactions, may offer
new therapeutic approaches.
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AIM
To characterize the gut microbiome and metabolome in H. pylori patients in a
socioeconomically challenged and underprivileged inner-city community.

Supported by The Camden Health

METHODS
Stool samples from 19 H. pylori patients and 16 control subjects were analyzed.
16S rRNA gene sequencing was performed on normalized pooled amplicons
using the Illumina MiSeq System using a MiSeq reagent kit v2. Alpha and beta
diversity analyses were performed in QIIME 2. Non-targeted fatty acid analysis of
the samples was carried out using gas chromatography-mass spectrometry, which
measures the total content of 30 fatty acids in stool after conversion into their
corresponding fatty acid methyl esters. Multi-dimensional scaling (MDS) was
performed on Bray-Curtis distance matrices created from both the metabolomics
and microbiome datasets and a Procrustes test was performed on the metabolomics and microbiome MDS coordinates.
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RESULTS
Fecal microbiome analysis showed that alpha diversity was lowest in H. pylori
patients over 40 years of age compared to control subjects of similar age group.
Beta diversity analysis of the samples revealed significant differences in microbial
community structure between H. pylori patients and control subjects across all
ages. Thirty-eight and six taxa had lower and higher relative abundance in H.
pylori patients, respectively. Taxa that were enriched in H. pylori patients included
Atopobium, Gemellaceae, Micrococcaceae, Gemellales and Rothia (R. mucilaginosa).
Notably, relative abundance of the phylum Verrucomicrobia was decreased in H.
pylori patients compared to control subjects. Procrustes analysis showed a significant relationship between the microbiome and metabolome datasets. Stool
samples from H. pylori patients showed increases in several fatty acids including
the polyunsaturated fatty acids (PUFAs) 22:4n6, 22:5n3, 20:3n6 and 22:2n6, while
decreases were noted in other fatty acids including the PUFA 18:3n6. The pattern
of changes in fatty acid concentration correlated to the Bacteroidetes:Firmicutes
ratio determined by 16S rRNA gene analysis.
CONCLUSION
This exploratory study demonstrates H. pylori-associated changes to the fecal
microbiome and fecal fatty acid metabolism. Such changes may have implications
for improving eradication rates and minimizing associated negative distal outcomes.
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Core Tip: Helicobacter pylori (H. pylori) infects half of the world’s population and is
associated with various diseases, including malignancy. Research of microbiome and
metabolomic changes associated with H. pylori may hold therapeutic potential. We
sought to characterize the fecal microbiome and fatty acid metabolism among H. pylori
patients in our community. We observed differences in alpha and beta diversity among
H. pylori patients compared to controls, particularly for those over 40 years old.
Changes in several fecal fatty acids, including those associated with anti-inflammatory
activity, were observed. Our findings may have implications for improving H. pylori
eradication and minimizing associated negative distal outcomes.
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INTRODUCTION

Peer-review report’s scientific
quality classification

Helicobacter pylori (H. pylori), a bacterium found in the stomach of roughly half of the
world’s population, is associated with various gastrointestinal diseases, including
peptic ulcers, non-ulcer dyspepsia, gastric adenocarcinoma, and gastric lymphoma.
Although many infections are asymptomatic, eradication of H. pylori has been shown
to reduce the incidence of gastric cancer and is thus universally recommended[1]. For
decades, clarithromycin-based triple therapy was considered the first-line therapy for
H. pylori eradication and associated gastric cancer prevention. Following the global
trend in emerging antibiotic resistance, rates of clarithromycin, metronidazole, and
levofloxacin resistance among H. pylori strains have increased markedly, causing an
alarmingly high rate of eradication failure[2]. In the absence of universally available
antibiotic susceptibility testing, current guidelines advocate for the use of empiric
quadruple therapy strategies; however, the efficacy of these regimens may be limited
by dual resistance, local availability, and patient adherence[3].
As the burden of antibiotic resistance increases, the need for new adjunct therapies
designed to facilitate H. pylori eradication and reduce negative distal outcomes
associated with infection has become more pressing. The relationship between H.
pylori and the microbiome has garnered particular attention of late[4]. With the advent
of high throughput 16S rRNA gene sequencing methods and open-source software for
subsequent analysis and visualization, researchers have been able to characterize
changes in microbial diversity and community structure, as well as specific taxa that
are differentially abundant in association with particular phenotypes[5]. Many studies
have focused on H. pylori-mediated changes to the gastric microbiome, in which data
have demonstrated variable effects on multiple metrics of microbial diversity and
community structure[4]. H. pylori-associated gastric dysbiosis is particularly significant
in the context of studies which suggest increased relative abundance of particular taxa,
including Lactobacillus and Lachnospiraceae, among patients who develop premalignant
lesions and gastric cancer[6,7]. H. pylori-associated gastric dysbiosis has also prompted
researchers to evaluate the adjunct therapeutic role of probiotics, which may increase
the rate of H. pylori eradication and limit negative side effects of antibiotic treatment[811].
More recently, researchers have also focused on the impact of H. pylori infection on
distal gut, i.e., fecal microbiota. Despite H. pylori’s role as an almost exclusively gastric
pathogen, animal and clinical studies have demonstrated alterations in distal gut
microbiota associated with H. pylori infection[12-15]. The mechanisms by which gastric
H. pylori infection may influence the distal gut microbiome are unclear, although
authors have speculated that multiple factors, including alterations in hydrochloric
acid secretion, gastrointestinal hormones, and immune regulation, may be involved
[12-14]. As stated above, microbiome modulation with probiotics may have a role in
improving eradication rates and minimizing adverse effects of antibiotics. Additionally, H. pylori-mediated changes to the distal gut microbiome may be significant in
the context of research that implicates gut dysbiosis in the development of colorectal
cancer (CRC)[16]. Indeed, authors of a large case-control study found that seropositivity for the H. pylori virulence factor VacA was associated with increased odds of
CRC[17]. The well-documented associations between gut dysbiosis, type 2 diabetes,
and metabolic syndrome has also prompted speculation about the role of H. pyloriassociated gut dysbiosis in diabetes, which has been associated with H. pylori infection
[18-21]. Further characterization of the interactions between H. pylori and the gut
microbiome, as well as the mechanisms underlying these interactions, may lead to a
better understanding of the role of microbiome modulation in H. pylori therapy, as
well as the development of novel therapies and screening tools aimed at the negative
distal outcomes associated with H. pylori infection, including CRC and metabolic
diseases.
Given the association between H. pylori infection and gastrointestinal inflammation,
attention has also been paid to compounds with anti-inflammatory activity, including
fatty acids. Polyunsaturated fatty acid (PUFA) supplementation in particular may
have therapeutic potential for H. pylori treatment via multiple mechanisms, including
suppression of inflammatory cytokines and enzymes and direct bacteriocidal effects
via disruption of cell membranes[22-24]. 10-hydroxy-cis-12-octadecenoic acid (10-HOE;
a linoleic acid derivative) and docosahexaenoic acid (DHA) have both been shown to
inhibit in vitro growth of H. pylori and gastric infection in mouse models[25,26].
Nevertheless, the effects of H. pylori infection on fatty acid metabolism in the gastrointestinal tract are not completely understood. Furthermore, the extent to which
such metabolomic changes may relate to alterations in the gastrointestinal microbiota
are unknown. Notably, short-chain fatty acids (SCFAs) produced by gut microbiota
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are thought to play a role in intestinal homeostasis, regulation of immune function,
and dysbiosis in the setting of inflammatory bowel disease, which is associated with
decreased levels of these important molecules[27,28]. Exploration of changes in fatty
acid production and metabolism associated with H. pylori-mediated alterations of the
fecal microbiome is warranted, as it may reveal strategies to inhibit the cascade of
events leading to neoplasia.
Previously, we studied the pattern of H. pylori prevalence and antibiotic resistance
in our socioeconomically challenged and underprivileged inner-city community[29].
As a next step, we then sought to characterize the gut microbiome associated with H.
pylori infection in our patients. We further explored interactions among H. pylori
infection, the gut microbiota, and the gut metabolome by comparing stool fatty acid
profiles between subjects with and without H. pylori infection. Our overarching goal is
to identify potential targets for intervention that could improve H. pylori eradication
rates and limit associated negative distal outcomes.

MATERIALS AND METHODS
Patients and sample collection
Patients presenting to the Cooper Digestive Health Institute in Camden, New Jersey
were recruited for our study. H. pylori patients at least 18 years of age and diagnosed
via biopsy between June 1, 2017 and December 31, 2019, were eligible for inclusion.
Patients less than 18 years old, pregnant women, patients taking antibiotics at the time
of recruitment or sampling, and non-English speaking patients were excluded from
participation. H. pylori-positive patients are identified in our electronic medical record
system (EPIC) by ICD-9 codes of 041.86, 531.90, 535.60, 795.79, 008.47, 531.00, V12.08.
Histological examination of the biopsied samples showed positive outcome indicating
H. pylori infection. Control participants were recruited from a healthy population, also
seen at Cooper Health Institute for well visits. The control subjects were screened for
lack of previous history and current documentation for H. pylori infection as well as
lack of any GI-related symptoms before recruitment. Their stools were tested by reverse transcription-polymerase chain reaction (PCR) based biprobe assay for presence
of H. pylori DNA[30]. None of the stool samples from the control subjects showed
presence of H. pylori DNA. Informed consent was obtained by one of several Institutional Review Board (IRB)-approved team members. Surveys about demographic
information and relevant medical history were collected. Information on diagnosis,
disease features, medication, history of antibiotic use, and treatment regimen were
collected from the electronic medical record. Patients were asked to provide a stool
sample before initiating eradication therapy, and samples were collected and stored in
Stool Nucleic Acid Collection and Preservation Tubes (Cat. No. 45630, 45660, Norgen
Biotek Corp., Thorold, Ontario, Canada) prior to freezing at –80 ℃ as described
previously[29].

Processing of samples and 16S rRNA gene sequencing
Total genomic bacterial DNA extraction was performed from frozen fecal samples
using the Qiagen DNeasy PowerSoil HTP Kit (Cat. No. 12955-4, Qiagen, Valencia, CA,
United States). Adequate DNA yield was confirmed using NanoDrop spectrophotometry. For high throughput sequencing, 515F–806R Golay barcodes were used to
target the hypervariable V4 region of the 16S rRNA gene, which is highly conserved
and ideal for gut microbiome analysis. Marker genes in isolated DNA were PCRamplified using GoTaq Master Mix (Cat. No. M5133, Promega, Madison, WI, United
States) as described in Caporaso et al[31]. PCR products were cleaned and normalized
using the SequalPrepTM Normalization Plate Kit (Cat. No. A1051001, ThermoFisher,
Waltham, MA, United States) following the manufacturer’s instructions. Purification
of PCR product amplicons was performed with the QIAquick PCR Purification Kit
(Cat. No. 28104, Qiagen). Quantification of the PCR amplified library was performed
with the InvitrogenTM Quant-iTTM PicoGreen TM dsDNA Assay Kit (Cat. No. P7589,
ThermoFisher). 16S rRNA gene sequencing was performed on normalized pooled
amplicons using the Illumina MiSeq System using a MiSeq reagent kit v2 (300 cycles;
Cat. No. MS-102-2002, Illumina Inc.). FASTQ files for reads 1 (forward), 2 (reverse),
and the index (barcode) read were generated using the BCL-to-FASTQ file converter
bcl2fastq (ver. 2.17.1.14, Illumina, Inc.). Sequencing of the samples was conducted at
the University of Colorado Boulder BioFrontiers Next-Gen Sequencing core facility.
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Sequencing data analysis
Analysis was performed using Python-based packages (Python 3.6.12), QIIME 2 2019.4
(denoising and taxonomy assignment), Quantitative Insights Into Microbial Ecology
(QIIME) 2 2020.11 (statistical testing), and Linear Discriminant Analysis (LDA) using
LDA Effect Size (LEfSe)[32,33]. Sequences were de-multiplexed, then filtered and
clustered into sub-operational taxonomic units (sOTUs) using QIIME 2 DADA2[34]. A
masked phylogenetic tree was created using MAFFT via QIIME2[35,36]. Taxonomy
was assigned using a naïve-Bayes classifier based on the latest Greengenes 16S rRNA
gene database available as of August 2019 via the QIIME 2 interface (gg_13_8). Additional Python packages (SciPy.stats, Scikit-bio) were used for statistical tests on
QIIME 2-generated data. Inter-class comparisons were made based on attributes of our
population including: H. pylori status, gender, age group, race, education, and alcohol
use. Alpha and beta diversity analyses were performed in QIIME 2, rarefied to an even
sampling depth of 22400[37]. Alpha diversity was assessed by Faith’s phylogenetic
diversity, chao1 index, and observed OTUs. Differences in alpha diversity between
groups were determined by Kruskal-Wallis non-parametric rank test for categorical
variables or by Fisher Z transformation on Spearman rho values for differences
between alpha diversity correlations with numeric data across groups. Bacterial
composition (beta diversity) was analyzed by principal coordinate analyses (PCoA) of
both unweighted and weighted unique fraction metric (UniFrac) phylogenetic distance
matrices[38-41]. Beta diversity was assessed for statistical significance between groups
using Monte Carlo permutations [Adonis and permutational multivariate analysis of
variance (PERMANOVA)], and dispersion of group samples was assessed using permutational analysis of multivariate dispersions (PERMDISP)[42,43]. Comparisons of
relative abundances of microbial taxa between groups were performed using LEfSe
with the Segata et al[44] online interface. Taxa with an LDA value of 2.0 or greater and
a two-tailed P value ≤ 0.05 with Kruskal-Wallis and pairwise Wilcoxon analyses were
considered significantly enriched. The code is available at https://github.com/
sterrettJD/H-pylori-microbiome-analysis.

Non-targeted fatty acid analysis
Collected fecal samples were stored at –80 ℃ until analysis. Sample preparation and
analysis were performed using gas chromatography-mass spectrometry (GC-MS) by
Metabolon, Inc. (Durham, NC, United States). This method (Metabolon TAM112-002)
measures the total content of 30 fatty acids in stool samples after conversion into their
corresponding fatty acid methyl esters (FAMEs). The measured concentrations are
provided in weight corrected μg/g of sample. NQ (not quantified-below the lower
limit of quantification) values were treated as a concentration of 0.001 mg/mL.
Briefly, stool samples were homogenized and the suspension was weighed out in a
100 mg aliquot in a test tube. Liquid/Liquid extraction was performed to extract fatty
acids and remove the nucleic acid preservative. A 250 μL aliquot of each extract was
transferred to a clean analysis tube. The solvent was removed by evaporation under a
stream of nitrogen. Internal standard solution was added to the dried sample extracts,
quality controls (QCs), and calibration standards. The solvent was again removed by
evaporation under a stream of nitrogen. The dried samples and QCs were subjected to
methylation/transmethylation with methanol/sulfuric acid, resulting in the formation
of the corresponding methyl esters (FAME) of free fatty acids and conjugated fatty
acids. The reaction mixture was neutralized and extracted with hexanes. An aliquot of
the hexanes layer was injected onto a 7890A/5975C GC-MS system (Agilent Technologies, Santa Clara, CA, United States). Mass spectrometric analysis was performed in
the single ion monitoring positive mode with electron ionization. Quantitation was
performed using both linear and quadratic regression analysis generated from fortified
calibration standards prepared immediately prior to each run. Raw data were collected
and processed using Agilent MassHunter GC-MS Acquisition B.07.04.2260 and Agilent
MassHunter Workstation Software Quantitative Analysis for GC-MS B.09.00/ Build
9.0.647.0. Data reduction was performed using Microsoft Office 365 ProPlus Excel.
Volcano plot data are included as Supplementary Tables 1-3 (Supplementary Table 1:
Volcano plot data with all Helicobacter data set; Supplementary Table 2: Volcano plot
data with High Bacteroidetes; Supplementary Table 3: Volcano plot data with High
Firmicutes).

Procrustes analysis
Multi-dimensional scaling (MDS, using the Python package Scikit-learn) was performed on Bray-Curtis distance matrices created from both the fecal metabolome and
fecal microbiome datasets (using the Python package SciPy.distance), and a Procrustes
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test was performed on the metabolomics and microbiome MDS coordinates. As
described by Peres-Neto and Jackson, a Procrustes randomization test (PROTEST) was
performed by randomly sampling the MDS coordinates and performing a Procrustes
test on the reordered coordinates 10000 times, and the P value was calculated based on
the portion of randomized Procrustes tests with resulting m2 (Gower’s statistic) scores
lower than the Procrustes m2 score of the observed datasets[45].

Ethics approval
This study received approval by the Cooper Health System IRB (17-077EX) and all the
steps were carried out as per the standards set by the IRB.

RESULTS
Fecal microbiome analysis
Selected demographic attributes of our participants are presented in Table 1. Fecal
microbiome analysis of 35 stool samples collected from 19 H. pylori patients and 16
healthy control subjects was carried out. The mean number of reads per sample was
269462 with a minimum of 22483 reads/sample. Rarefaction was set to 22400 for even
sampling based on this minimum. We analyzed the association of each of the factors
included in Table 1 with alpha and beta diversity (via Kruskal-Wallis and PERMANOVA for nominal variables or via Spearman correlation and Mantel test for
numerical variables, respectively). Age was the only factor that showed statically
significant differences (P value of ≤ 0.05) in alpha diversity in the H. pylori patients
compared to the control participants, with H. pylori patients over 40 years of age
having lower richness than control participants over 40 years of age. Significant
differences in community composition and group dispersion were seen between H.
pylori patients and control participants.
Information was collected about each participant regarding (1) If they had been
treated for H. pylori infection in the past; (2) If so, the date infection was diagnosed; (3)
Treatments given; and (4) Outcomes: Eradication testing with dates. Only one patient
had H. pylori infection 10 years ago and had successfully completed treatment at that
time. History about antibiotic treatments for any infection and proton pump inhibitors
(PPIs) use for both H. pylori patients and control subjects in the past five years was also
documented and these data values were included in the statistical analyses. Our
statistical analyses showed that the differences seen in H. pylori patients were not due
to the previous treatments.

Analysis of alpha diversity
Chao1 index alpha diversity between H. pylori patients and control subjects and regression analysis of observed OTUs by age are shown in Figure 1. Alpha diversity,
which estimates the diversity of a microbial community within a sample, incorporates
the number of different OTUs and their respective abundance in each sample. Alpha
diversity was lowest in H. pylori patients over 40 years of age, who had significantly
lower Chao1 scores compared to control subjects over 40 years of age (Kruskal-Wallis
H = 6.036, P = 0.014). H. pylori patients over 40 years old also had lower Chao1 scores
approaching statistical significance when compared to H. pylori patients under 40
(Kruskal-Wallis H = 2.813, P = 0.094). Additionally, the correlation of age with observed OTUs (Figure 1B), Faith’s phylogenetic diversity, and Chao1 was consistently
different between H. pylori patients vs control subjects, as evidenced by a Fisher Z
transformation on Spearman rank correlation rho values (observed OTUs: H. pylori rho
= –0.21 vs control rho = 0.50, Fisher P = 0.041; Faith: H. pylori rho = –0.04 vs control rho =
0.57, Fisher P = 0.067; Chao1: H. pylori rho = –0.15 vs control rho = 0.44, Fisher P =
0.097).

Analysis of beta diversity
Next we analyzed beta diversity of our samples, which estimates how samples differ
from each other. An unweighted UniFrac PCoA plot of H. pylori patients vs control
subjects is shown in Figure 2. Adonis testing revealed that current H. pylori infection
represented 7% of the variation in unweighted UniFrac beta diversity (F = 2.523, R2 =
0.071, P = 0.002). Additionally, unweighted UniFrac PERMANOVAs identified significant differences between H. pylori patients and control subjects (F = 2.523, P =
0.001). Furthermore, unweighted UniFrac PERMDISP did not reveal differences in
dispersion among H. pylori patients vs control subjects (F = 0.0506, P = 0.809), but
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Table 1 Patient demographics and clinical characteristics
Total (n = 35)

H. pylori patients (n = 19)

Control (n = 16)

Male

19 (54)

13 (68)

6 (38)

Female

16 (46)

6 (32)

10 (62)

18-40

15 (43)

3 (16)

12 (75)

> 40

20 (57)

16 (84)

4 (25)

Less than high school

2 (6)

2 (11)

0 (0)

High school

12 (34)

11 (58)

1 (6)

Undergraduate

4 (11)

2 (11)

2 (13)

Graduate

15 (43)

3 (16)

12 (75)

Post-graduate

1 (3)

0 (0)

1 (6)

African American

8 (23)

6 (32)

2 (12)

Asian American

2 (6)

0 (0)

2 (12)

Caucasian

13 (37)

1 (5)

12 (75)

Non-White Hispanic

8 (23)

8 (42)

0 (0)

Other

3 (9)

3 (16)

0 (0)

Smoker

5 (14)

4 (21)

1 (6)

Past H. pylori treatment

1 (3)

1 (5)

0 (0)

Duodenal ulcer

1 (3)

1 (5)

0 (0)

Non-ulcer dyspepsia

14 (40)

10 (53)

4 (25)

Sex, n (%)

Age, n (%)

Highest education, n (%)

Race, n (%)

H. pylori: Helicobacter pylori.

weighted UniFrac PERMDISP did (F = 6.82955, P = 0.017). We also explored the effect
of the use of PPIs via beta diversity analysis as PPIs are the medications commonly
given to H. pylori patients and we had previously noted their influence on the antibiotic resistance of H. pylori[29]. Unweighted UniFrac PERMANOVA identified
differences between PPI users and non-users across all participants (F = 1.939, P =
0.012), though the magnitude of the effect was smaller than that seen for H. pylori
infection as described above. It should also be noted that only four H. pylori patients
and one control subject were on PPI at the time of study and sample collection, so its
contribution to the results described here may not be significant.

LDA effect size
LEfSe scores for taxa that were differentially distributed across H. pylori patients vs
control subjects are shown in Figure 3. Thirty-eight taxa had lower relative abundance
in H. pylori patients relative to healthy control subjects, and six taxa had higher relative
abundance in H. pylori patients relative to healthy control subjects. Taxa that were
enriched in H. pylori patients include Atopobium, Gemellaceae, Micrococcaceae, Gemellales and Rothia (R. mucilaginosa). Figure 4 shows the arcsin square root transformed relative abundances of each phylum, grouped by H. pylori status. Notably,
relative abundance of the phylum Verrucomicrobia, and its main constituent, Akkermansia muciniphila, was decreased in H. pylori patients compared to control subjects.

Procrustes analysis
The Procrustes randomization test was carried out to investigate the relationship
between the fecal microbiome and fecal metabolome. Procrustes analysis identified a
significant relationship between the two datasets, as the resulting P value of 0.017
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Figure 1 Chao1 index alpha diversity and observed operational taxonomic units by Helicobacter pylori status stratified by age. A: Chao1
index alpha diversity is compared between Helicobacter pylori (H. pylori) patients (blue) and control subjects (orange), subgrouped by age. H. pylori patients over 40
years old (n = 16) had significantly lower Chao1 scores compared to control subjects over 40 (n = 4) (Kruskal-Wallis H = 6.036, P = 0.014). Boxes represent 1st and
3rd quartiles, and central lines represent median values. Whiskers represent non-outlier high and low values. Points show outliers, which were determined by having a
distance from the 1st or 3rd quartile greater than 1.5 times the interquartile range; B: Observed operational taxonomic units (operational taxonomic units) are compared
between H. pylori patients (blue, n = 19) and control subjects (orange, n = 16), as a function of age. Shading around the regression lines indicates 95% confidence
intervals. OTU: Operational taxonomic units; H. pylori: Helicobacter pylori.

Figure 2 Beta diversity analysis by unweighted UniFrac principal coordinate analysis. Unweighted principal coordinate analysis (PCoA) plot is
shown comparing Helicobacter pylori (H. pylori) patients (blue, n = 19) to control subjects (red, n = 16). Significant differences between H. pylori patients and control
subjects were identified by unweighted UniFrac PERMANOVA (F = 2.523, P = 0.001). The proportion of variance explained by each principal coordinate axis is
denoted in the corresponding axis label; PCo1 explains 16.95% of the variability and PCo2 explains 9.13% of the variability. H. pylori: Helicobacter pylori.

indicates that the correspondence of each participant’s fecal microbiome to their fecal
metabolome was better than 98% of randomly sampled simulations (Figure 5).

Fecal fatty acid analysis
To evaluate the impact of H. pylori infection on fatty acid composition, we performed
non-targeted metabolomics analysis of a panel of 30 fatty acids including long chain
fatty acids (LCFAs), monounsaturated fatty acids (MUFAs) and PUFAs. We prepared
a volcano plot evaluating changes in fatty acid profile for the entire population of H.
pylori patient samples relative to healthy control subjects (Figure 6A). In addition, we
prepared separate volcano plots for subgroups of the H. pylori patients with high
Bacteroidetes and high Firmicutes based on 16S rRNA gene analysis (Figure 6B and C).
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Figure 3 Linear discriminant analysis effect size scores for taxa enriched in Helicobacter pylori or control participants. Linear discriminant
analysis effect size (LEfSe) scores for taxa that were differentially distributed across Helicobacter pylori (H. pylori) patients (n = 19) vs control subjects (n = 16) via
Kruskal-Wallis and Wilcoxon tests with two-tailed α = 0.05. Negative values represent taxa that were enriched in H. pylori patients, whereas positive values represent
taxa that were enriched in control subjects. Error bars represent a 95% confidence interval and are only present if the listed taxonomic identity was the lowest level
classified for multiple operational taxonomic units highlighted by LEfSe. Color represents the phylum. H. pylori: Helicobacter pylori.

See Supplementary Tables 1-3 for the full volcano plot data. Volcano plots allow for
the plotting of P values vs fatty acid fold change from control samples for all evaluated
fatty acids.
Stool samples from H. pylori patients showed increases in several fatty acids
including the PUFAs 22:4n6, 22:5n3, 20:3n6 and 22:2n6 while decreases were noted in
fatty acids including the PUFA 18:3n6, relative to healthy control subjects. The pattern
of changes in fatty acid concentration was correlated to the Bacteroidetes:Firmicutes
ratio (determined by 16S rRNA gene analysis). Among the sub-population of H. pylori
patients identified to have high Bacteroidetes (Bacteroidetes:Firmicutes ratio ≥ 1
standard deviation above the ratio in control participants, n = 7) we found several fatty
acids that were diminished relative to control participants including the LCFAs 24:0,
22:0 and 15:0 along with MUFAs 20:1n9 and 18:1n9. By contrast, in the sub-population
of H. pylori patients identified to have high Firmicutes (Firmicutes:Bacteroidetes ratio ≥
1 standard deviation above ratios in control participants; n = 4) a distinct set of fatty
acids were found to be significantly increased and decreased relative to control
participants. In this subpopulation of H. pylori patients we observed increases in the
PUFA 22:2n6 and decreases in PUFAs 18:3n6 and 20:4n3 relative to control participants.
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Figure 4 Transformed relative abundances of phyla grouped by Helicobacter pylori infection. Arcsin square root transformed relative abundances
of each phylum, grouped by Helicobacter pylori (H. pylori) status. Bacterial relative abundances of H. pylori patients (n = 19) are shown in blue, whereas healthy
controls (n = 16) are shown in orange. Boxes represent the 1st and 3rd quartiles, and vertical lines in the middle of the boxes represent median values. Whiskers
represent the lowest and highest non-outlier values. Points show outliers, which were determined by having a distance from the 1st or 3rd quartile greater than 1.5
times the interquartile range. Of note, relative abundances of Verrucomicrobia were significantly lower in H. pylori patients compared to healthy controls (KruskalWallis H = 4.455, P = 0.034). H. pylori: Helicobacter pylori.

DISCUSSION
As little is known about the microbiome of H. pylori patients in an underprivileged
community, this study is useful due to its exploratory nature. A sample size
calculation for microbiome analysis was not thus performed prior to collecting
samples. Casals-Pascual et al[46] outline that in human microbiome studies knowledge
of the baseline microbiome diversity and composition, along with knowledge of the
magnitude of changes that confer clinically relevant outcomes are important for
determining sample size. However, this could not easily be predicted in our sample
demographic due to lack of previous research. Though the effects of H. pylori and low
socioeconomic status (SES) on the gut microbiome have been investigated separately
in previous studies, the two states (H. pylori infection and low SES) could potentially
have conflicting relationships with diversity and composition, making it difficult to
determine the baseline microbiome diversity and composition without large assumptions. Thus, much of this study provides the baseline to characterize the microbiome of
H. pylori patients in an underserved population, which was previously understudied
to a degree by which sample size calculations would have required a large number of
assumptions. Though the power is likely weak in this study, especially for post-hoc
analyses such as alpha diversity in H. pylori patients over 40 years of age vs control
participants over 40 years of age, multiple lines of evidence, including both the
Kruskal-Wallis test with age group and the Spearman correlation with actual age
support the relationship in our sample. These results can provide a basis for future
study design and power calculations.
Our sample size is modest in part due to the limitations posed by the socioeconomic
and cultural attributes of our patient population and logistic challenges associated
with sample collection. Camden County has the lowest median income and highest
poverty and unemployment rates in southern New Jersey. It also has the lowest
educational attainment and the greatest socioeconomic disparities among ethnic
minority groups. More than one third of the population in Camden City, where our
hospital is located, lives below the national poverty line, and the median household
income is USD $26105[47]. Our local community is thus considered one of the poorest
and most economically distressed communities in the United States. A significant
fraction of adults over 25 years old (almost one quarter) have not completed high
school. It is possible that this influences patients’ appreciation of the relevance of the
study and willingness to participate. A significant portion of potential participants
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Figure 5 Procrustes-transformed Bray-Curtis multi-dimensional scaling of microbiome and metabolome. Connections between the fecal
microbiome and fecal metabolome Bray-Curtis multi-dimensional scaling plots. The microbiome data shown here have been transformed by the Procrustes analysis
to minimize disparity between the two datasets, and lines have been drawn to indicate microbiome and metabolome from the same participants. Orange dots
represent the microbiomes, whereas blue triangles represent the metabolomes. The Procrustes randomization test showed a significant relationship between the
datasets (m2 = 0.86, P = 0.017). MDS: Multi-dimensional scaling.

Figure 6 Volcano plots of composition of evaluated fatty acids. A: Control vs entire Helicobacter pylori (H. pylori) patient group; B: Control vs sub-group
of H. pylori patients identified as having high ratio of Bacteroidetes to Firmicutes (n = 7 of 19 patients); C: Control vs sub-group of H. pylori patients identified as
having high ratio of Firmicutes to Bacteroidetes (n = 4 of 19 patients). Selected long-chain fatty acids (green), monounsaturated fatty acids (blue) and polyunsaturated
fatty acids (red) are highlighted. H. pylori: Helicobacter pylori.

were excluded due to non-English-speaking status, thus being unable to partake in the
informed consent process. Logistic challenges imposed by the process of stool sample
collection also limited the number of subjects. A large number of potential participants
were unable to return to the clinic for stool sample delivery due to poor transportation
access or inability to leave employment or domestic responsibilities during the window for sample collection (after diagnosis but prior to initiation of antibiotics).
Nonetheless, the present study yielded meaningful results.
H. pylori infection was associated with significantly decreased fecal microbial
diversity relative to over the age of 40 years. Among all participants, correlations
between age and multiple metrics of microbial alpha diversity were consistently
different between H. pylori patients and control subjects. H. pylori was also shown to
account for a significant portion of the variation in beta diversity between infected
patients and control subjects. Collectively, these results may suggest an H. pylorimediated alteration of the fecal microbiome that progresses with age. While other
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authors have attributed decreased diversity of gastric microbiota to the ability of H.
pylori to outcompete other species, secretion of antibacterial peptides, and local pH
alterations, the mechanisms by which H. pylori affect distal gut microbiota remain
unclear[4,48-50]. Although our study was not designed to uncover these mechanisms,
multiple factors hypothesized by other authors, including alterations in hydrochloric
acid secretion, gastrointestinal hormones, and immune regulation, may be involved in
the mediation of distal gut dysbiosis[12-14]. The impact of H. pylori on fecal microbial
diversity observed in our study may be reversible, as a recent study showed that H.
pylori eradication could restore gastric microbial diversity to levels seen in uninfected
controls[51].
Less likely is the possibility that the data reflect a preceding decrease in gut microbial diversity that facilitates H. pylori infection, potentially mediated by other
factors or exposures that accumulate with age. In other words, patients who experience decreased gut microbial diversity as they age, potentially mediated by diet or
chronic inflammation, may be more prone to H. pylori infection, particularly by midadulthood. In our previous study of 2014 H. pylori patients, we observed that 80% of
our patients were above the age of 40 years, consistent with studies showing increased
prevalence of H. pylori infection with age in both developing and developed countries
[29,52]. Antibiotic exposure is known to alter the gut microbiome, and increased rates
of antibiotic-resistant H. pylori among older adults have been attributed to increased
antibiotic use compared to younger patients[53,54]. Conceivably, decreased gut microbial diversity induced by cumulative antibiotic exposure could create an intragastric niche for H. pylori, and antibiotic-resistant H. pylori strains in particular, to
thrive. However, H. pylori infection is thought to be acquired in infancy and carried
through to adulthood, and this observation would not be consistent with preceding
microbiome alteration facilitating de novo H. pylori infection in adulthood[55].
LEfSe showed that multiple taxa were differentially enriched or depleted in stool
from H. pylori patients compared to controls. The significance of differential expression
of these taxa is unknown; however, certain taxa stand out. The enrichment of
Atopobium in H. pylori patients is notable in the context of a metagenomic analysis that
revealed increased Atopobium parvulum abundance among patients with colorectal
intramucosal carcinomas[56]. Although H. pylori is predominantly associated with
gastric cancers, a recent meta-analysis suggested a significantly increased risk of CRC
as well, and our data suggest that H. pylori-associated increases in Atopobium abundance may have a role in the distal gut carcinogenesis[57].
Over-representation of Rothia mucilaginosa, a commensal oral microbe, has previously been observed in fecal samples from patients with primary sclerosing cholangitis
(PSC)[58]. Because of the sensitivity of R. mucilaginosa to gastric fluid, Bajer et al[58]
hypothesized that its presence in PSC patients represented contamination of the
intestine via previous endoscopic retrograde cholangiopancreatography. The enrichment of Rothia sp. in fecal samples from our H. pylori patients may reflect the
potent gastric acid suppression by H. pylori, allowing translocation of swallowed oral
flora to the distal gut. The clinical consequences of the colonization of the distal gut by
Rothia sp. are unknown, although the bacteria has been implicated as a cause of
myriad syndromes, including dental caries, pneumonia, and bacteremia, particularly
in immunocompromised patients[59]. The increased abundance of Gemellaceae in H.
pylori patients is consistent with the observation of increased organisms from the
Gemella genus in patients with current H. pylori infection reported by Gao et al[60].
Increased relative abundance of Gemellaceae in the Crohn’s ileum has been reported
by other groups[61,62].
Interestingly, the phylum Verrucomicrobia was significantly depleted in H. pylori
patients. Verrucomicrobia includes Akkermansia muciniphila, a mucus-residing commensal bacterium of the large intestine. A. muciniphila is an obligate chemoorganotroph, utilizing mucus as a sole carbon, nitrogen, and energy source that produces
SCFAs including acetate, propionate, and, to a smaller extent, 1,2-propanediol[63,64].
Our study was not designed to study this aspect in detail, but the decreased relative
abundance of Verrucomicrobia may suggest disruption of the gut mucosal environment by H. pylori. In a mouse stress model, exposure to chronic psychosocial stress
resulted in expansion of Helicobacter spp., which has been demonstrated to proliferate
in response to glucocorticoid administration as well as psychosocial stress exposure
[65]. Specifically, stress-induced increases in Helicobacter spp. were associated with
increases in other Proteobacteria spp., including unidentified genera belonging to the
Enterobacteraceae and Desulfovibrionaceae families. Concurrently, relative abundance
of Mucispirillum, an obligate mucus-residing bacterium, decreased; a decline of Mucispirillum in rodents is associated with early disruption of the gastrointestinal surface
mucus layer and a prolonged delay to recovery after the period of pathogen clearance
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[66]. Potential disruption of the gut mucosa by H. pylori infection is also consistent
with decreased relative abundance of Faecalibacterium prausnitzii. F. prausnitzii is an
important gram-positive human commensal that produces butyrate and other SCFA
through the fermentation of dietary fiber. Reduced relative abundance of F. prausnitzii
has been associated with inflammatory conditions including Crohn’s disease, obesity,
asthma, and stress-related psychiatric disorders in which inflammation is a risk factor,
such as major depressive disorder[67-70].
Strategies to promote increased gastric microbial diversity among patients with H.
pylori infection, particularly those over 40 years of age, may hold therapeutic potential
in eradicating infection, and some clinical trials with adjunctive probiotic formulas
have shown promising results in this regard[71]. Likewise, treatment of gut dysbiosis
in patients with H. pylori infection may limit its associated pathologies. Reduced fecal
microbiome diversity is associated with multiple disease markers including increased
adiposity, insulin resistance, dyslipidemia, and a pro-inflammatory state[72]. H. pylori
infection is associated with higher rates of diabetes, specifically, and addressing gut
dysbiosis in such patients could conceivably aid primary dietary and pharmacologic
strategies to achieve glycemic control and insulin sensitivity[20]. Rehabilitation of the
gut microbiota in patients with H. pylori may also have a role in minimizing the risk of
malignancy. Mouse studies suggest that the carcinogenic effects of H. pylori partly
depend on interactions with the gut microbiome, and persistent infection with H.
pylori may create a niche favorable for taxa that are found in increased abundance in
gastric cancer, including Lactobacillus and Lachnospiraceae[73,74]. It has been suggested
that lactic acid bacteria can influence gastric cancer by a number of mechanisms such
as (1) Supply of exogenous lactate, that acts as a fuel source for cancer cells; (2)
Production of reactive oxygen species and N-nitroso compounds; and (3) By allowing
colonization of carcinogenic non-H. pylori bacteria[75]. Accordingly, reversal of
abnormalities in gut microbiota associated with H. pylori may also limit its carcinogenic potential. Finally, consideration must be given to the effects of H. pylori
treatment on the gut microbiome, as data suggest that current therapies may be
associated with dysbiosis and subsequent adverse effects[76]. Several factors including
lifestyle and diet can act as confounders in analysis of the diversity and composition of
the gut microbiome. However, given the challenges associated with controlling for
such variables, their presence should not prohibit drawing meaningful conclusions
from significant observations of gut dysbiosis in association with H. pylori.
While evaluating changes in the LCFAs palmitic (16:0) and stearic (18:0) concentrations, we found that palmitic acid concentrations were increased in our test samples
compared to control samples [625.23 ± 598.82 mg/g (n = 18) vs 334.10 ± 284.58 mg/g (n
= 12)], whereas concentrations of stearic acid were comparable between populations.
Interestingly, when we evaluated the high Firmicutes (> 1.4:1 Firmicutes:Bacteroidetes,
n = 4) sub-group compared to the high Bacteroidetes (> 2.7:1 Bacteroidetes:Firmicutes,
n = 7) sub-group of our test population, we found the concentrations of both these
LCFAs to be diminished in the high Bacteroidetes population while the concentrations
of both were enhanced in the high Firmicutes sub-population. This is consistent with
previous studies in mice where administration of LCFA-rich diets resulted in an
observed increase in Firmicutes to Bacteroidetes ratio[77]. Ktsoyan et al[78] implicated
a characteristic profile of serum LCFA concentrations in association with H. pylori
infection compared to healthy controls. It is plausible that diet can modulate the
impact of H. pylori on the gut microbiome, which in turn may relate to different
disease phenotypes, i.e., asymptomatic infection, peptic ulcer disease, and gastric
cancer.
The accumulation of the saturated LCFAs is regulated under normal physiological
conditions by desaturation of 16:0 to 16:1n7, elongation of 16:0 to 18:0 and/or desaturation of 18:0 to 18:1n9 which can be further elongated to 20:1n9 (Figure 7). While
only small changes in concentrations of these MUFAs were noted between our H.
pylori patients and control subjects, the changes in MUFA concentrations in our high
Firmicutes and high Bacteroidetes sub-populations showed more significant and
consistent changes across the series of MUFAs. The concentration of 16:1n7, 18:1n9 and
20:1n9 were decreased in the high Bacteroidetes sub-group, whereas these MUFAs
were slightly increased in the high Firmicutes sub-group. Interestingly, this contrasts
published data on the benefits of high MUFA diets in animal models and humans. In
previous studies, high MUFA diets have been reported to lead to increased ratios of
Bacteroidetes to Firmicutes and were correlated with reductions in several disease
indicators[77]. Together, these observations may suggest that either the patients in our
high Bacteroidetes sub-population have severely limited MUFA production/intake,
contrasting previous work on MUFA rich diets or that the endogenous biosynthetic
pathways for MUFA production are dysregulated in this patient population.
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Figure 7 Major metabolic pathways. Selected long-chain fatty acids (no fill), monounsaturated fatty acids (light grey fill) and polyunsaturated fatty acids (dark
grey fill) are highlighted. Although many of the fatty acids shown may be supplemented by diet, key parent members of these pathways acquired from de novo
lipogenesis and/or diet are indicated. DNL: De novo lipogenesis.

The range of PUFAs observed endogenously have essential physiological roles and
are produced from dietary alpha-linolenic acid (18:3n3) and linoleic acid (18:2n6). We
observed that both of these dietary PUFAs were increased in our test samples compared to the control samples. In humans, C18:3n3 is converted through multiple steps
to eicosapentaenoic acid (20:5n3) and DHA (22:6n3), whereas 18:2n6 proceeds to
produce arachidonic acid (AA, 20:4n6) (Figure 7). As these two biosynthetic pathways
share enzymes for their respective dehydration and elongation steps, they are antagonistic to each other. In general, a high 18:3n3 (n-3 fatty acid) diet is correlated with
positive physiological effects whereas a high 18:2n6 (n-6 fatty acid) diet is correlated
with metabolic dysbiosis and negative physiological effects[79,80]. Accordingly a
balanced dietary intake of n-6/n-3 fatty acids is recommended to be 1:1-2:1, although
the average ratio in a typical Western diet has been reported to be > 15:1[81]. In
accordance with published ratios for n-6/n-3 fatty acid intake in Western diets, we
find the ratio of 18:2n6/18:3n3 to be 22:1 in our control samples and 15:1 in our H.
pylori patient test samples.
Endogenously, the essential dietary fatty acid 18:3n3 undergoes multiple dehydration and elongation steps to produce docosapentaenoic acid (DPA, 22:5n3) and
DHA (22:6n3). For all intermediates along this biosynthetic pathway, with exception to
18:3n3 and 22:5n3, we observe concentrations at or below the limit of quantification for
the majority of samples making an evaluation of the individual steps of this biosynthesis pathway difficult.
Contrasting the low concentrations observed for 18:3n3 and fatty acids produced
along this biosynthetic pathway, higher overall concentrations were observed for fatty
acids derived from 18:2n6, perhaps reflecting the higher concentration of dietary n-6
fatty acids as described earlier. In humans, the dietary fatty acid, 18:2n6 undergoes
dehydration to produce 18:3n6. This intermediate undergoes a subsequent elongation
to produce 20:3n6, which is dehydrated to 20:4n6 (AA). Alternatively, 18:2n6 can
undergo elongation first to produce 20:2n6, which is dehydrated to produce 20:3n6
(Figure 7).
We found that the early steps in the metabolism of 18:2n6 were significantly
impacted in all of our H. pylori samples by comparison of downstream fatty acid
metabolites to controls. Most notably, in all H. pylori test samples the concentration of
18:3n6 was significantly diminished. Concentration of 18:3n6 was 10.7 ± 18.2 mg/g (n
= 12) in the control samples and 0.36 ± 1.50 mg/g (n = 18) in the test samples. While
we would anticipate that this deficiency in dehydration of 18:2n6 would lead to lower
levels of fatty acid metabolites downstream of 18:3n6, this is not the case. In fact, by
the following biosynthetic step, i.e., elongation to produce 20:3n6, the fatty acid
concentration of 20:3n6 in test samples was found to be higher than in controls. These
higher concentrations were also reflected in arachidonic acid (20:4n6) and adrenic acid
(22:4n6). It is plausible that the alternative d-8-desaturase mediated route via 20:2n6 may
be prominent in these H. pylori patient samples, which are marked by a deficiency in d6-desaturase mediated pathway via 18:3n6[82]. We observed a striking decrease in the
concentration of the PUFA C18:3n6 in H. pylori infected patients. Interestingly, among
the multiple liposomal fatty acids evaluated by Thamphiwatana et al[83], only the
linolenic acid formulation (C18:3) showed bactericidal activity by impacting the H.
pylori membrane structure and stability.
As the burden of antibiotic resistance grows, populations like ours are impacted
greatly by the high prevalence of H. pylori colonization. As eradication by a one-sizefits-all approach becomes more and more difficult, it becomes even more important to
look towards strategies that can provide insight into community attributes that can
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help guide targeted therapies, predict likelihood of treatment outcomes, and possibly
create strategies towards mitigating the impact of increased antibiotic usage. A greater,
more individualized understanding of gut microbiome features among patients experiencing H. pylori colonization, especially in our underserved population, will pave
the way for better community impact and reduce healthcare burdens of repeated
treatment and mounting antibiotic resistance. As gut dysbiosis is inextricably tied not
only to H. pylori infection but also to the use of antibiotics itself, the cycle of treatment
and re-treatment may very well only further exacerbate vulnerability to enteric
pathogens. Our results add to the growing evidence suggesting that H. pylori is
associated with alterations in distal gut microbiota, particularly in those over 40 years
of age. Strategies to better understand gut dysbiosis features among affected groups
may create opportunities for improving eradication rates and reducing negative
associated distal outcomes.

CONCLUSION
This exploratory study demonstrates H. pylori-associated changes to the fecal microbiome and fecal fatty acid metabolism. Such changes may have implications for
improving eradication rates and minimizing associated negative distal outcomes.

ARTICLE HIGHLIGHTS
Research background
Helicobacter pylori (H. pylori), a bacterium that infects approximately half of the world’s
population, is associated with various gastrointestinal diseases, including peptic
ulcers, non-ulcer dyspepsia, gastric adenocarcinoma, and gastric lymphoma. Following the global trend in emerging antibiotic resistance, rates of clarithromycin,
metronidazole, and levofloxacin resistance among H. pylori strains have increased
markedly, causing high rates of eradication failure.

Research motivation
As the burden of antibiotic resistance increases, the need for new adjunct therapies
designed to facilitate H. pylori eradication and reduce negative distal outcomes associated with infection has become more pressing. Characterization of the interactions
between H. pylori, the fecal microbiome, and fecal fatty acid metabolism, as well as the
mechanisms underlying these interactions, may offer new therapeutic approaches.

Research objectives
The aim of this study is to characterize the fecal microbiome and metabolome in H.
pylori patients in a socioeconomically challenged and underprivileged inner-city community.

Research methods
Stool samples from 19 H. pylori patients and 16 control subjects were analyzed. 16S
rRNA gene sequencing was performed on normalized pooled amplicons using the
Illumina MiSeq System using a MiSeq reagent kit v2. Alpha and beta diversity analyses were performed in QIIME 2. Non-targeted fatty acid analysis of the samples was
carried out using gas chromatography-mass spectrometry, which measures the total
content of 30 fatty acids in stool after conversion into their corresponding fatty acid
methyl esters. Multi-dimensional scaling (MDS) was performed on Bray-Curtis
distance matrices created from both the metabolomics and microbiome datasets and a
Procrustes test was performed on the metabolomics and microbiome MDS coordinates.

Research results
Fecal microbiome analysis showed that alpha diversity was lowest in H. pylori patients
over 40 years of age compared to control subjects of similar age group. Beta diversity
analysis of the samples revealed significant differences in microbial community
structure between H. pylori patients and control subjects across all ages. Thirty-eight
and six taxa were identified by Linear Discriminant Analysis (LDA) using LDA Effect
Size to be enriched in H. pylori patients vs control individuals, respectively. Taxa that
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were enriched in H. pylori patients included Atopobium, Gemellaceae, Micrococcaceae,
Gemellales and Rothia (R. mucilaginosa). Notably, relative abundance of the phylum
Verrucomicrobia was decreased in H. pylori patients compared to control subjects.
Procrustes analysis showed a significant relationship between the microbiome and
metabolome datasets. Stool samples from H. pylori patients showed increases in
several fatty acids including the polyunsaturated fatty acids (PUFAs) 22:4n6, 22:5n3,
20:3n6 and 22:2n6, while decreases were noted in other fatty acids including the PUFA
18:3n6. The pattern of changes in fatty acid concentration correlated to the Bacteroidetes:Firmicutes ratio determined by 16S rRNA gene analysis.

Research conclusions
The study suggests H. pylori-associated changes to the fecal microbiome and fecal fatty
acid metabolism. Such changes may have implications for improving eradication rates
and minimizing associated negative distal outcomes.

Research perspectives
Future study with greater power should be directed to confirming the distal gut dysbiosis and changes to fecal fatty acid metabolism seen in our exploratory analysis of
patients with H. pylori infection, as well as towards exploring the relationships between such phenomena and eradication success, colorectal cancer, and metabolic disease.
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